Introduction
============

Esophageal adenocarcinoma (EAC) is a highly lethal malignancy that occurs mainly in the distal esophagus and gastroesophageal junction ([@b1-ol-0-0-10808]). EAC is rare in China; however, it represents the predominant type of esophageal cancer in North America and Europe. In these continents, the overall incidence of EAC has rapidly increased over the past three decades at a rate (5--10%) greater than that of any other major cancer and the incidence rate is higher in white males compared with that in white females ([@b2-ol-0-0-10808]--[@b4-ol-0-0-10808]). The reason for this increase is not entirely understood. Previous studies have reported that EAC differs from esophageal squamous cell carcinoma (ESCC) in terms of genetic and environmental risk factors such as tobacco use, alcohol, obesity and germline mutations ([@b5-ol-0-0-10808],[@b6-ol-0-0-10808]). Systematic therapy for EAC typically includes endoscopic mucosal resection, surgical resection, chemoradiotherapy and neoadjuvant chemotherapy; however, the mortality rate remains high and the overall 5-year survival rate is 17% in the United States ([@b7-ol-0-0-10808]). Although endoscopy can accurately diagnose early-stage EAC, most patients are diagnosed with regional metastasis or distant metastasis, which are positively correlated with a considerable decline in the 5-year survival rate ([@b8-ol-0-0-10808]). There is therefore an urgency to identify novel potential diagnostic and prognostic biomarkers for EAC.

Long non-coding RNAs (lncRNAs) represent a new class of non-coding RNAs (ncRNAs) and are defined as transcripts \>200 nucleotides in length ([@b9-ol-0-0-10808]). Unlike their shorter counterparts, including microRNAs (miRNAs), the roles and underlying mechanisms of lncRNAs in human disease remain largely unknown. Due to improvements in DNA sequencing techniques, numerous lncRNAs have been discovered. In addition, an increasing number of lncRNAs have been identified in human cancer, such as HAGLR opposite strand lncRNA overexpression in gastric cancer ([@b10-ol-0-0-10808]). Previous studies have focused on the biological function and underlying molecular mechanism of lncRNAs in various types of cancer, including colorectal cancer, gastric cancer, hepatocellular carcinoma, renal cell carcinoma, prostate carcinoma and EAC ([@b11-ol-0-0-10808]--[@b17-ol-0-0-10808]). Although studies reported that lncRNAs can be involved in the development and progression of ESCC ([@b6-ol-0-0-10808],[@b14-ol-0-0-10808]), only a few studies have determined the function of lncRNAs in EAC ([@b5-ol-0-0-10808],[@b18-ol-0-0-10808]).

Emerging technologies have increased our ability to determine the functions of cancer-associated lncRNAs. Significant progress towards understanding the underlying molecular mechanism by which lncRNAs can regulate miRNA function has therefore been made. Salmena *et al* ([@b19-ol-0-0-10808]) proposed a competing endogenous RNA (ceRNA) language where protein coding genes, microRNAs and lncRNAs communicate with each other by competitively binding to shared miRNA response elements (MREs). Competing endogenous RNA networks comprise a new regulatory network of mRNAs and non-coding RNAs, which reveals a greatly expanded role for lncRNAs in human disease ([@b20-ol-0-0-10808]). This hypothesis has been experimentally validated. For example, Cesana *et al* ([@b21-ol-0-0-10808]) identified a muscle-specific lncRNA named linc-MD1, which regulates the expression of mastermind-like 1 and myocyte-specific enhancer factor 2C by serving as a 'sponge' for miR-133. Furthermore, Qu *et al* ([@b22-ol-0-0-10808]) demonstrated that lncARSR mediates sunitinib resistance in renal cell carcinoma by competitively binding to miR-34/miR-449 to promote AXL receptor tyrosine kinase and c-MET expression. Exploration of RNA cross-talk offers therefore insights into cancer diagnosis and therapy. An lncRNA-miRNA-mRNA ceRNA network has therefore been constructed for various types of human cancer, in particular for ESCC ([@b23-ol-0-0-10808]--[@b26-ol-0-0-10808]); however, such a network has not yet been described for EAC.

In order to systematically describe EAC-associated pseudogenes and to construct a ceRNA network, the present study comprehensively analyzed RNA sequencing (RNA-Seq) transcript data that were obtained from The Cancer Genome Atlas (TCGA) esophageal cancer project (<https://www.cancer.gov/types/esophageal>). The database includes lncRNA, microRNA and mRNA data and clinical information from patients with EAC. The present study included 79 EAC tumor and 11 adjacent non-tumor esophagus tissue samples. By using publicly available RNA-Seq data from TCGA, some EAC-associated lncRNAs, mRNAs and miRNAs were identified based on the ceRNA hypothesis. Furthermore, 561 differentially expressed lncRNAs (DElncRNAs), 1,289 differentially-expressed mRNAs (DEmRNAs) and 44 differentially-expressed miRNAs (DEmiRNAs) were identified. Subsequently, five dysregulated lncRNAs, 13 mRNAs and 32 miRNAs were identified and included in a constructed ceRNA network based on lncRNA-miRNA interactions predicted by miRcode v11 ([www.mircode.org/](www.mircode.org/)). Potential prognostic biomarkers were then identified by exploring the influence of dysregulated RNAs on overall survival using the univariate Cox proportional hazards regression model and Kaplan-Meier curve analysis. The results from this comprehensive analysis provided the foundation for deeper understanding of the cancer-associated lncRNA functions in EAC and revealed potential prognostic biomarkers.

Materials and methods
=====================

### Patients and samples

Data for 187 patients with esophageal cancer were obtained from the TCGA data portal (<https://portal.gdc.cancer.gov/>). The exclusion criteria were as follows: i) Patients with ESCC or undetermined pathological classification; and ii) samples without corresponding RNA-Seq and miRNA-Seq data. Overall, data from 79 patients with EAC were enrolled in the present study. This study followed the publication guidelines provided by TCGA (<http://cancergenome.nih.gov/publications/publicationguidelines>).

### RNA-Seq data

RNA-Seq and miRNA-Seq data (level 3) were downloaded from 90 tissue samples of the TCGA database, including 79 EAC samples and 11 adjacent normal samples. The gene expression profiles generated from Illumina Hiseq platforms (Illumina, Inc.) were all publicly available data.

### Analysis of DEmRNAs, DElcnRNAs and DEmiRNAs

The raw count data were processed with edgeR v3.25.0 (Bioconductor), which is a package based on the R language (v3.5.0) ([@b27-ol-0-0-10808]) for differential gene expression analysis. For all P-values, a false discovery rate (FDR) was applied to correct the statistical significance of multiple testing. Genes with \>2.0 fold change (FC) and FDR-adjusted P\<0.01 were considered significant. The volcano plot and heat map were designed to visualize the results using ggplots v3.0, which is a package based on the R language.

### Association between DElncRNAs and patient prognosis

All patients were classified into high or low lncRNA-expression groups according to the median. Kaplan-Meier and log-rank methods were used to test differences between the two groups. P\<0.05 was considered to indicate a statistically significant difference.

### Construction of the ceRNA network

Three calculations were performed to construct the ceRNA network as follows: i) Cancer-associated lncRNA filtration, where lncRNAs with FC\>2.0 (either up- or downregulated) and FDR-adjusted P\<0.01 were considered as cancer-associated lncRNAs \[to improve data reliability, cancer-associated lncRNAs that were not annotated by GENCODE (<http://www.gencodegenes.org/>) were excluded\]; ii) lncRNA-miRNA interactions were predicted by miRcode (<http://www.mircode.org/>) and starBase (<http://starbase.sysu.edu.cn/>); and iii) target mRNAs of DEmiRNAs were predicted using the three bioinformatics databases miRDB (<http://mirdb.org/>), miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/php/index.php>) and TargetScan (<http://www.targetscan.org>). Gene Oncology (GO) was analyzed using Database for Annotation, Visualization, and Integrated Discovery bioinformatics tools (DAVID; v6.8; <http://david.ncifcrf.gov>). In order to improve the consistency of the bioinformatics analysis, the target genes were retained. A network graph was constructed and visualized using Cytoscape v3.5.1 (<https://cytoscape.org/>).

Results
=======

### Patient characteristics

The detailed clinical information and pathological characteristics of the patients included in the present study, including sex, age at diagnosis, metastasis status, lymph node status and tumor-node-metastasis stage, are presented in [Table I](#tI-ol-0-0-10808){ref-type="table"}. The median age for all patients was 69 years (range, 27--86 years). The median overall survival was 14.29 months (range 0.36--83.18 months).

### Identification of DElncRNAs

lncRNAs with FDR-adjusted P\<0.01 and FC \>2.0 were considered to be differentially expressed. A total of 561 DElncRNAs were identified, of which 217 were upregulated and 344 were downregulated ([Table SI](#SD1-ol-0-0-10808){ref-type="supplementary-material"}). A volcano plot was therefore constructed ([Fig. 1A](#f1-ol-0-0-10808){ref-type="fig"}) to visually describe the FDRs and FCs. In addition, a heat map was designed ([Fig. 1B](#f1-ol-0-0-10808){ref-type="fig"}) to highlight the top 100 significant DElncRNAs according to the FDR-adjusted P-values.

To explore the potential lncRNAs that could possess prognostic abilities, the expression profiles of 561 lncRNAs and corresponding clinical data were analyzed using Kaplan-Meier Curve. The results demonstrated that 26 lncRNAs were positively correlated with overall survival (OS; P\<0.05; [Fig. 2](#f2-ol-0-0-10808){ref-type="fig"}). Among these 26, 12 lncRNAs, AC007128.1, AC079354.3, AC246680.1, AL009178.2, AL135924.2, AL138789.1, AP003356.1, AP0033469.2, GK-IT1, HOTAIR, LINC01114 and LINC01768, were negatively correlated with OS ([Fig. 2A](#f2-ol-0-0-10808){ref-type="fig"}). Conversely, the remaining 14 lncRNAs, AC004585.1, AC016395.1, AC024337.2, AC087491.1, AC093583.1, AC104211.1, AL022316.1, AL031429.1, CYP1B1-AS1, LINC00163, LINC00906, LINC01695, SLCO4A1-AS1 and UG0898H09, were positively correlated with OS ([Fig. 2B](#f2-ol-0-0-10808){ref-type="fig"}).

### Identification of DEmRNAs

The RNA expression levels in 79 EAC tumor samples and 11 normal samples were analyzed. With a cut-off value of FDR-adjusted P\<0.01 and FC \>2.0, 367 upregulated and 922 downregulated mRNAs were identified ([Table SII](#SD1-ol-0-0-10808){ref-type="supplementary-material"}). A volcano plot was therefore constructed to visualize the results ([Fig. 3A](#f3-ol-0-0-10808){ref-type="fig"}). The top 100 significant DEmRNAs were then highlighted by plotting FDR-adjusted P-values in a heat map ([Fig. 3C](#f3-ol-0-0-10808){ref-type="fig"}).

To analyze the DEmRNA functions, enrichment analysis based on enriched functional GO modules was performed. The results demonstrated that the DEmRNAs were significantly enriched in the 'chemokine-mediated signaling pathway' (GO: 0070098), 'plasma membrane' (GO: 0005886) and 'calcium ion binding' (GO: 0005509) GO terms under 'biological process', 'cellular component' and 'molecular function', respectively ([Fig. 3B](#f3-ol-0-0-10808){ref-type="fig"}).

### Identification of DEmiRNAs

In order to design a ceRNA network for EAC, the miRNA expression profiles between tumor samples and normal samples were compared. Subsequently, 44 DEmiRNAs, including 28 upregulated and 16 downregulated were identified ([Fig. 4A and C](#f4-ol-0-0-10808){ref-type="fig"}). The mRNAs that were targeted by the 44 DEmiRNAs from miRDB, miRTarBase and TargetScan were then screened. To improve data reliability, mRNAs that were not included in the set of 1,289 DEmRNAs were excluded. Eventually, 13 DEmiRNAs remained in the ceRNA network ([Fig. 4B](#f4-ol-0-0-10808){ref-type="fig"}).

In order to identify the DEmRNAs that may have potential prognostic ability, the expression profiles of the 13 DEmRNAs included in the ceRNA network were analyzed using Kaplan-Meier curve. The results demonstrated that the expression profiles of three DEmRNAs were positively correlated with OS (P\<0.05). Two of these DEmRNAs, angiopoietin 2 and interleukin 11 (IL11) were negatively correlated with OS, whereas neurotrophic receptor tyrosine kinase 2 (NTRK2) was positively correlated with OS ([Fig. 4D](#f4-ol-0-0-10808){ref-type="fig"}).

To identify the lncRNA-miRNA interactions in EAC, the potential MREs in DElncRNAs were screened using miRcode. For miRNA-mRNA interactions, miRDB, miRTarBase, and TargetScan were used to identify the DEmRNAs targeted by DEmiRNAs. The results are listed in [Tables II](#tII-ol-0-0-10808){ref-type="table"} and [III](#tIII-ol-0-0-10808){ref-type="table"}.

### ceRNA network construction

In order to improve knowledge on DElncRNA function in EAC, a dysregulated lncRNA-miRNA-mRNA ceRNA network based on the aforementioned data (presented in [Tables II](#tII-ol-0-0-10808){ref-type="table"} and [III](#tIII-ol-0-0-10808){ref-type="table"}) was constructed. The results demonstrated that in the ceRNA network, interaction of five DEmiRNAs with 37 DElncRNAs was predicted, according to the results retrieved from miRcode. The ceRNA network is presented in [Fig 5](#f5-ol-0-0-10808){ref-type="fig"}.

Discussion
==========

lncRNAs represent a crucial category of non-coding genes in the transcriptome that act as pivotal regulators of cell physiology and pathology in human cancer by mediating gene expression through multiple mechanisms ([@b28-ol-0-0-10808]). The dysregulation of lncRNA expression is involved in the pathogenesis of various types of solid tumor ([@b29-ol-0-0-10808],[@b30-ol-0-0-10808]). Numerous novel biological functions have been attributed to lncRNAs, which have become the focal point of many studies ([@b10-ol-0-0-10808],[@b17-ol-0-0-10808]). The ceRNA hypothesis describes regulatory networks among protein-coding mRNAs and non-coding RNAs, including miRNAs and lncRNAs at the post-transcription level. According to this hypothesis, changes in the expression of one or multiple miRNA targets can alter the number of unbound miRNAs and lead to observable changes in miRNA activity. The various transcripts from the transcriptome communicate with one another by competitively binding to shared MREs ([@b20-ol-0-0-10808]). ceRNA networks in human cancer include cancer-associated lncRNAs, microRNAs and mRNAs. A previous study demonstrated a miRNA-lncRNA-mRNA interaction in ESCC ([@b31-ol-0-0-10808]). However, the ceRNA network in EAC remains poorly understood.

At present, since lncRNAs are able to regulate miRNA functions by competitively binding to shared MREs in mRNA, they are considered as diagnostic and prognostic biomarkers. Numerous well-studied lncRNAs have been identified as potential targets or powerful predictors in various types of cancer, including LINC00668, H19 and UCA1 ([@b32-ol-0-0-10808]--[@b34-ol-0-0-10808]). However, studies on EAC remain rare. Based on the RNA-Seq data and clinical data from 79 patients with EAC, the present study demonstrated that 26 cancer-associated lncRNAs may affect the OS of patients with EAC. In particular, the results from this study reported that two DElncRNAs, CYP1B1-AS1 and HOTAIR, were not only identified as part of the ceRNA network, but were also positively and negatively correlated with OS, respectively, which suggested that these two lncRNAs may serve as essential oncogenes and as prognostic markers in EAC.

HOTAIR is a highly studied lncRNA. Previous studies demonstrated that it serves a role in the development and progression of various types of solid tumor, including renal cell carcinoma, colorectal cancer, breast cancer, gastric cancer, non-small cell lung cancer, cervical cancer and ovarian epithelial carcinoma ([@b35-ol-0-0-10808]--[@b45-ol-0-0-10808]). In addition, Ren *et al* ([@b46-ol-0-0-10808]) demonstrated that HOTAIR can control the cell cycle by acting as a competing endogenous 'sponge' to downregulate miR-1 and upregulate cyclin D1 in ESCC. The present study reported that HOTAIR expression was upregulated in EAC tumor tissues. In addition, patients with highly expressed HOTAIR had worse survival outcomes. HOTAIR may therefore compete with miR-301b and miR-204 to regulate chordin like 1, NTRK2, IL11, neuronal pentraxin 1, homeobox C8 and solute carrier family 22 member 6 expression. Although these mRNAs have been identified as aberrantly expressed, their roles have not been fully investigated in EAC.

In addition to HOTAIR, LINC00163 and SLCO4A1-AS1 have also been reported to be associated with cancer prognosis. Guo *et al* ([@b47-ol-0-0-10808]) demonstrated that the LINC00163 level is significantly decreased in lung cancer tissues and cell lines following bioinformatics and reverse transcription-quantitative PCR analyses. LINC00163 expression was lower in metastatic tissues compared with non-metastatic tissues, and a higher LINC00163 expression in patients with lung cancer could predict a better prognosis. Yang *et al* ([@b48-ol-0-0-10808]) reported that SLCO4A1-AS1 expression was more upregulated in bladder cancer tissues compared with that in adjacent normal tissues, and that SLCO4A1-AS1 overexpression is associated with poor prognosis and tumor metastasis. Yu *et al* ([@b49-ol-0-0-10808]) demonstrated that a high SLCO4A1-AS1 expression level is associated with bladder cancer progression and that SLCO4A1-AS1 promotes malignant phenotypes of bladder cancer cells via the miRNA-335-5p/OCT4 axis.

To confirm the accuracy of the ceRNA network prediction presented in this study, interactions among lncRNAs, miRNAs and mRNAs in EAC were measured. Only cancer-associated lncRNAs and miRNAs with \>2.0 FC and FDR \<0.01 were selected. These non-coding genes were then annotated by GENCODE. Interactions among lncRNAs, miRNAs and mRNAs were predicted by experimentally conformed algorithms or by using miRDB, miRcode, miRTarBase and TargetScan databases. In the present study, cancer-associated lncRNAs in EAC were identified based on the RNA-Seq data of 79 EAC tissues and 11 normal tissues. Subsequently, cancer-associated miRNAs and mRNAs were identified. Eventually, interactions between lncRNAs, miRNAs and mRNAs was identified by constructing an lncRNA-miRNA-mRNA ceRNA network. A total of 37 DElncRNAs, five miRNAs and 13 mRNAs were selected to construct this newly-identified ceRNA-mediated gene regulatory network. This network included numerous active lncRNA-miRNA-mRNA interactions that may be used as prognostic biomarkers in EAC.

In conclusion, the present study identified some cancer-associated lncRNAs and revealed their potential use in prognosis prediction. In particular, some cancer-associated lncRNAs may serve as ceRNAs. The ceRNA network that was built in the present study may help understanding the mechanisms involved in the development and progression of EAC.
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![Volcano plot and heat map of lncRNA analysis. (A) Plots of log2FC vs. log~10~(FDR) for DElncRNAs. Red dots represent significantly upregulated lncRNAs and green dots represent significantly downregulated lncRNAs. (B) The top 100 significantly DElncRNAs were visualized by heat map. Each column represents one sample and each row represents a single lncRNA. DElncRNAs, differentially expressed lncRNAs; FC, fold change; FDR, false discovery rate; lncRNA, long non-coding RNA.](ol-18-05-4798-g00){#f1-ol-0-0-10808}

###### 

Kaplan-Meier survival curves for lncRNAs associated with OS (P\<0.05). (A) A total of 12 lncRNAs were negatively correlated with OS. lncRNA, long non-coding RNA; OS, overall survival. (B) A total of 14 lncRNAs were positively correlated with overall survival. lncRNA, long non-coding RNA; OS, overall survival.
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![DEmRNAs in esophageal adenocarcinoma. (A) Volcano plot of log2FC vs. log~10~(FDR) for DEmRNAs. Red dots represent significantly upregulated mRNAs, and green dots represent significantly downregulated mRNAs. (B) The enriched Gene Ontology terms of target genes. (C) The top 100 significant DEmRNAs were visualized by heat map. Each column represents one sample and each row represents a single mRNA. DEmRNAs, differentially expressed mRNAs; FC, fold change; FDR, false discovery rate.](ol-18-05-4798-g03){#f3-ol-0-0-10808}

![DEmiRNAs in esophageal adenocarcinoma. (A) Volcano plot of log2FC vs. log~10~(FDR) for differentially expressed miRNAs. Red dots represent significantly upregulated miRNAs and green dots represent significantly downregulated miRNAs. (B) Venn analysis of overlapping genes between statistically significant mRNAs and target genes of DEmiRNAs. (C) Significant DEmiRNAs were visualized by heat map. Each column represents one sample and each row represents an individual miRNA. (D) Kaplan-Meier survival curves of three target genes in overall survival prediction (P\<0.05). DEmiRNAs, differentially expressed miRNAs; FC, fold change; FDR, false discovery rate; ANGPT2, angiopoietin 2; IL-11, interleukin-11; NTRK2, neurotrophic receptor tyrosine kinase 2; miRNA, microRNA.](ol-18-05-4798-g04){#f4-ol-0-0-10808}

![Differentially expressed lncRNA-mediated competing endogenous RNA network in EAC. Global view of the lncRNA-miRNA-mRNA network in EAC. The nodes highlighted in red indicate an increased level of expression and the nodes highlighted in blue indicate a decreased level of expression. lncRNAs, miRNAs, and mRNAs are indicated as diamonds, rounded rectangles and ellipses, respectively. EAC, esophageal adenocarcinoma; lncRNA, long non-coding RNA; miRNA/miR, microRNA.](ol-18-05-4798-g05){#f5-ol-0-0-10808}

###### 

Clinical characteristics of patients with esophageal adenocarcinoma.

  Characteristics           No. cases   \%
  ------------------------- ----------- ------
  Age at diagnosis, years               
    \<60                    26          32.9
    ≥60                     53          67.1
  Sex                                   
    Male                    11          13.9
    Female                  68          86.1
  Metastasis                            
    M0                      57          72.2
    M1                      10          12.7
    MX                      10          12.7
  Lymph node status                     
    N0                      22          27.8
    N1                      44          55.7
    N2                      5           6.3
    N3                      5           6.3
    NX                      3           3.8
  Stage                                 
    I                       9           11.4
    II                      22          27.8
    III                     26          32.9
    IV                      5           6.3
  T stage                               
    T0                      1           1.3
    T1                      19          24.1
    T2                      10          12.7
    T3                      46          58.2
    T4                      1           1.3
    TX                      2           2.6
  Histological grade                    
    G1                      1           1.3
    G2                      28          35.4
    G3                      24          30.4
    GX                      26          32.9

###### 

Potential miRNAs that may target cancer-associated lncRNAs by miRNA response elements.

  lncRNAs         miRNAs
  --------------- -----------------------------------------------------
  LINC00525       hsa-mir-301b, hsa-mir-383
  PART1           hsa-mir-301b, hsa-mir-145, hsa-mir-204
  C2orf48         hsa-mir-372, hsa-mir-372
  LINC00483       hsa-mir-372
  C20orf166-AS1   hsa-mir-301b, hsa-mir-372
  C15orf54        hsa-mir-301b, hsa-mir-372
  C8orf31         hsa-mir-372, hsa-mir-204
  AP002478.1      hsa-mir-372
  LINC00314       hsa-mir-372, hsa-mir-204
  LINC00501       hsa-mir-301b, hsa-mir-204
  C1orf137        hsa-mir-204, hsa-mir-383
  MUC19           hsa-mir-301b, hsa-mir-372, hsa-mir-145, hsa-mir-204
  KRBOX1-AS1      hsa-mir-301b, hsa-mir-372, hsa-mir-204
  LINC00114       hsa-mir-204
  SNHG14          hsa-mir-301b, hsa-mir-372, hsa-mir-145, hsa-mir-204
  LINC00337       hsa-mir-372, hsa-mir-145, hsa-mir-383
  HOTAIR          hsa-mir-301b, hsa-mir-204
  LINC00332       hsa-mir-204
  CYP1B1-AS1      hsa-mir-301b, hsa-mir-145, hsa-mir-204
  AC110491.1      hsa-mir-204
  LINC00494       hsa-mir-372, hsa-mir-145, hsa-mir-383
  LINC00299       hsa-mir-145, hsa-mir-204, hsa-mir-383
  CADM2-AS1       hsa-mir-301b, hsa-mir-145, hsa-mir-383
  AC011374.1      hsa-mir-372
  ADAMTS9-AS1     hsa-mir-301b, hsa-mir-145
  AC002464.1      hsa-mir-383
  AC007834.1      hsa-mir-301b
  ADAMTS9-AS2     hsa-mir-301b, hsa-mir-372, hsa-mir-145, hsa-mir-204
  GK-AS1          hsa-mir-145
  LIFR-AS1        hsa-mir-372, hsa-mir-204
  ALDH1L1-AS2     hsa-mir-301b, hsa-mir-372, hsa-mir-145
  PVT1            hsa-mir-372, hsa-mir-145, hsa-mir-383
  LINC00536       hsa-mir-204
  AC006487.1      hsa-mir-204
  AC090206.1      hsa-mir-204
  FAM181A-AS1     hsa-mir-204
  LINC00524       hsa-mir-204

lncRNA, long non-coding RNA; miRNA, microRNA.

###### 

Differentially expressed mRNAs targeted by differentially expressed miRNAs.

  miRNAs         mRNAs
  -------------- --------------------------------------------------
  hsa-mir-145    ANGPT2, PDGFD, DDC, MEST
  hsa-mir-148a   HOXC8, NPTX1
  hsa-mir-196b   HOXB7, IGF2BP3, HOXC8
  hsa-mir-204    HOXC8, NTRK2, SLC22A6, CHRDL1, IL11, NPTX1, CDH2
  hsa-mir-372    TMEM100, CADM2

miRNA, microRNA.
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